Faricimab for treatment-naive nAMD: 1- and 2-year outcomes and PS-OCT polarimetric entropy. Katabami T, Ota M, Saeki Y, Yashiro K, et al. Int Ophthalmol 2026;46:338.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Katabami T, Ota M, Saeki Y, Yashiro K, et al. Faricimab for treatment-naive nAMD: 1- and 2-year outcomes and PS-OCT polarimetric entropy. Int Ophthalmol 2026;46:338.
PMID: 42622722